tiprankstipranks
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

KPTI Stock Latest News

Karyopharm Therapeutics Board Member Resigns Amid Career Shift
Company AnnouncementsKaryopharm Therapeutics Board Member Resigns Amid Career Shift
10d ago
8K
KPTI
Karyopharm completes enrollment in Phase 3 Sentry trial
PremiumThe Fly
Karyopharm completes enrollment in Phase 3 Sentry trial
11d ago
KPTI
Cautious Hold on Karyopharm Therapeutics Amid Revenue Guidance Cut and Clinical Delays
PremiumRatings
Cautious Hold on Karyopharm Therapeutics Amid Revenue Guidance Cut and Clinical Delays
1M ago
KPTI
Karyopharm’s Earnings Call: Clinical Wins Amid Financial Strain
PremiumCompany Announcements
Karyopharm’s Earnings Call: Clinical Wins Amid Financial Strain
1M ago
KPTI
Karyopharm price target lowered to $25 from $42 at Baird
PremiumThe Fly
Karyopharm price target lowered to $25 from $42 at Baird
1M ago
KPTI
Karyopharm Therapeutics Reports Q2 2025 Earnings
PremiumCompany AnnouncementsKaryopharm Therapeutics Reports Q2 2025 Earnings
1M ago
KPTI
Karyopharm reports Q2 EPS ($4.32), consensus ($3.91)
Premium
The Fly
Karyopharm reports Q2 EPS ($4.32), consensus ($3.91)
1M ago
KPTI
Karyopharm backs FY25 revenue view $140M-$155M, consensus $147.08M
Premium
The Fly
Karyopharm backs FY25 revenue view $140M-$155M, consensus $147.08M
1M ago
KPTI
Is KPTI a Buy, Before Earnings?
PremiumPre-Earnings
Is KPTI a Buy, Before Earnings?
1M ago
KPTI
Karyopharm downgraded to Neutral from Buy at H.C. Wainwright
PremiumThe Fly
Karyopharm downgraded to Neutral from Buy at H.C. Wainwright
2M ago
KPTI
Karyopharm Therapeutics Explores Financing and Strategic Options
PremiumCompany Announcements
Karyopharm Therapeutics Explores Financing and Strategic Options
2M ago
8K
KPTI
Karyopharm assumed with a Buy at H.C. Wainwright
PremiumThe Fly
Karyopharm assumed with a Buy at H.C. Wainwright
2M ago
KPTI
Karyopharm Therapeutics Stockholders Approve Equity Plan Amendment
PremiumCompany AnnouncementsKaryopharm Therapeutics Stockholders Approve Equity Plan Amendment
4M ago
8K
KPTI
Karyopharm’s Earnings Call: Clinical Gains Amid Financial Strains
Premium
Company Announcements
Karyopharm’s Earnings Call: Clinical Gains Amid Financial Strains
4M ago
KPTI
Karyopharm abstract selected for presentation at 2025 EHA meeting
Premium
The Fly
Karyopharm abstract selected for presentation at 2025 EHA meeting
4M ago
KPTI
Karyopharm price target lowered to $33 from $43 at RBC Capital
PremiumThe Fly
Karyopharm price target lowered to $33 from $43 at RBC Capital
4M ago
KPTI
Karyopharm price target lowered to $42 from $54 at Baird
PremiumThe Fly
Karyopharm price target lowered to $42 from $54 at Baird
4M ago
KPTI
Karyopharm price target adjusted to $10 from $5 at Barclays
PremiumThe Fly
Karyopharm price target adjusted to $10 from $5 at Barclays
4M ago
KPTI
Karyopharm Therapeutics Reports Q1 2025 Earnings and Clinical Progress
PremiumCompany Announcements
Karyopharm Therapeutics Reports Q1 2025 Earnings and Clinical Progress
4M ago
KPTI
Karyopharm reports Q1 EPS ($2.77), consensus ($3.09)
PremiumThe FlyKaryopharm reports Q1 EPS ($2.77), consensus ($3.09)
4M ago
KPTI
Karyopharm sees 2025 revenue $140M-$155M, consensus $149.62M
Premium
The Fly
Karyopharm sees 2025 revenue $140M-$155M, consensus $149.62M
4M ago
KPTI
KPTI Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
KPTI Earnings this Week: How Will it Perform?
5M ago
KPTI

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >